Nephrotic Syndrome
📧 Sign up to get email alerts when something new happens for Nephrotic Syndrome.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2012-03-27FDA Approved: LASIX — Supplemental Application (Validus Pharmaceuticals LLC)
FDA approved a supplemental application for LASIX (furosemide) submitted by Validus Pharmaceuticals LLC.
-
CLINICAL_TRIALS trial_result · 2012-03-02Clinical Trial Update: Total Body Albumin Measurement Utilizing a Modification of the BVA 100 Blood Volume Analyzer
This completed trial evaluated a modification of the BVA-100 blood volume analyzer for measuring total body albumin, sponsored by Daxor Corp…
-
FDA approval · 2011-12-31FDA Approved: HYDROCHLOROTHIAZIDE — Supplemental Application (Solco Healthcare U.S., LLC)
FDA approves Solco Healthcare U.S., LLC's supplemental application for hydrochlorothiazide, enabling continued supply of the generic diureti…
-
FDA approval · 2011-12-14FDA Approved: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for the generic fixed-dose combination of spironolactone and hydrochlorothiazide from Sun Pharmaceut…
-
FDA approval · 2011-11-28FDA Approved: SPIRONOLACTONE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for spironolactone filed by Amneal Pharmaceuticals LLC, a generic product. The approval confirms cha…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2011-11-02Clinical Trial Update: The Efficacy and Tolerance of Tacrolimus Sustained-release Capsules on Refractory Nephrotic Syndrome (RNS) [Phase 3]
Phase 3 trial assessing the efficacy and tolerability of Tacrolimus sustained-release capsules in patients with refractory nephrotic syndrom…
-
CLINICAL_TRIALS trial_result · 2011-10-28Clinical Trial Update: Steroid Treatment for Kidney Disease [Phase 3]
A Phase 3 clinical trial update evaluating steroid treatment for kidney diseases (nephrotic syndrome and focal segmental glomerulosclerosis)…
-
FDA approval · 2011-09-21FDA Approved: TORSEMIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for torsemide from Teva Pharmaceuticals USA, Inc. This approval pertains to a supplemental submissio…
-
FDA approval · 2011-07-26FDA Approved: CHLOROTHIAZIDE SODIUM — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' original application for CHLOROTHIAZIDE SODIUM, a thiazide diuretic, for the treatment of hypert…
-
CLINICAL_TRIALS trial_result · 2011-07-14Clinical Trial Update: Prospective Study Evaluating the Effect of Repository Corticotropin in the Treatment of Various Nephrotic Syndromes [Phase 4]
Phase 4 prospective study evaluated repository corticotropin for various nephrotic syndromes. Sponsored by the Arizona Kidney Disease and Hy…
-
FDA approval · 2011-01-27FDA Approved: FUROSEMIDE — Supplemental Application (Solco Healthcare LLC)
FDA approved a supplemental application for furosemide from Solco Healthcare LLC under an ANDA, authorizing a manufacturing or labeling chan…
-
FDA approval · 2011-01-26FDA Approved: FUROSEMIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved Hikma Pharmaceuticals USA Inc.'s supplemental application for furosemide, a generic diuretic, under the existing ANDA.
-
FDA approval · 2011-01-26FDA Approved: FUROSEMIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for furosemide from Hikma Pharmaceuticals USA Inc., authorizing a change to the NDA (such as lab…
-
FDA approval · 2010-12-27FDA Approved: FUROSEMIDE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for furosemide filed by Chartwell RX, LLC, authorizing changes under the supplemental NDA. The appro…
-
FDA approval · 2010-10-18FDA Approved: LASIX — Supplemental Application (Validus Pharmaceuticals LLC)
The FDA approved a supplemental application for LASIX (furosemide) from Validus Pharmaceuticals LLC.
-
FDA approval · 2010-09-28FDA Approved: TORSEMIDE — Supplemental Application (Chartwell RX, LLC)
The FDA approved a supplemental application for torsemide submitted by Chartwell RX, LLC under ANDA 076894. The action approves changes to t…
-
FDA approval · 2010-07-02FDA Approved: SPIRONOLACTONE — Original Application (Amneal Pharmaceuticals LLC)
FDA approved Amneal Pharmaceuticals LLC's original application for generic spironolactone, establishing a bioequivalent product to the refer…
-
CLINICAL_TRIALS trial_result · 2010-06-08Clinical Trial Update: Fluid Balance, Hormones and Urine Proteomics in Nephrotic Syndrome in Childhood
A completed clinical trial examining fluid balance, hormones, and urine proteomics in childhood nephrotic syndrome.
-
CLINICAL_TRIALS trial_result · 2010-03-18Clinical Trial Update: Urinary Aquaporin 2 and Expression of the NPHS2 Gene in Adults Suffering From Nephrotic Syndrome
A completed clinical trial examining urinary Aquaporin 2 and NPHS2 gene expression in adults with nephrotic syndrome.
-
FDA approval · 2010-03-08FDA Approved: BUMETANIDE — Supplemental Application (Sagent Pharmaceuticals)
The FDA approved a supplemental application for Bumetanide submitted by Sagent Pharmaceuticals.
-
CLINICAL_TRIALS trial_result · 2010-03-02Clinical Trial Update: Glucocorticoid-induced Osteopenia in Children
A clinical trial update discusses glucocorticoid-induced osteopenia in pediatric patients, with focus on children with Crohn's disease or ne…
-
FDA approval · 2010-01-21FDA Approved: BUMEX — Supplemental Application (Validus Pharmaceuticals LLC)
FDA approved a supplemental application for Bumex (bumetanide) submitted by Validus Pharmaceuticals LLC.
-
FDA approval · 2009-10-16FDA Approved: CHLOROTHIAZIDE — Original Application (Fresenius Kabi USA, LLC)
FDA approves Fresenius Kabi USA, LLC's original abbreviated new drug application for chlorothiazide sodium, a thiazide diuretic. The product…
-
FDA approval · 2009-09-24FDA Approved: NEORAL — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for NEORAL (cyclosporine) from Novartis Pharmaceuticals Corporation, authorizing changes to the …
-
CLINICAL_TRIALS trial_result · 2009-09-23Clinical Trial Update: The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy [NA]
A completed clinical trial assessed whether eradicating Helicobacter pylori reduces proteinuria in patients with membranous nephropathy, nep…